NCT05408780View on ClinicalTrials.gov

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

August 13, 2022

Study Completion Date

October 24, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

AC-OLE-01-VA

formulation of tricaprilin or matching placebo

Trial Locations (1)

33126

Quotient Sciences Miami, Miami

Sponsors

Lead Sponsor

Cerecin
All Listed Sponsors
lead

Cerecin

INDUSTRY

NCT05408780 - A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects | Biotech Hunter | Biotech Hunter